[A double-blind cross-over trial of a new hypolipidaemic drug (author's transl)]. / Studio in doppio cieco ed in cross-over di un nuovo farmaco ipolipemizzante.

ABSTRACT

A double blind cross-over trial has been carried out on the effects of a nicotinic acid compound on 27 patients affected by hyperlipidemia. The subjects have been treated over one year according the following plan two peroids of 90 days each with the drug and two with placebo. The statistical analysis showed a significant reduction of serum cholesterol triglycerides, phospholipids and total lipids. In 4 patients out of 27, the treatment has not been completed because of drug intollerance.